文献速递肝病消化道肿瘤与早癌

肝细胞癌患者索拉非尼获益的预后因素与预测因素:两项III期研究分析

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
PubMed 文献 · J Hepatol · 2017-07-04

两项III期研究(SHARP与亚太)共827例不可切除肝细胞癌患者的汇总探索性分析显示,宏观血管侵犯、高甲胎蛋白和高中性粒细胞与淋巴细胞比值为总生存期较差的预后因素;索拉非尼在各亚组中均一致获益,无肝外转移、丙型肝炎病毒感染及较低中性粒细胞与淋巴细胞比值者获益更大。

要点

  • 宏观血管侵犯、高甲胎蛋白和高中性粒细胞与淋巴细胞比值为总生存期较差的预后因素。
  • 索拉非尼的总生存期获益在所有亚组中均一致观察到。
  • 无肝外转移、丙型肝炎病毒感染及较低中性粒细胞与淋巴细胞比值提示索拉非尼总生存期获益更大。

核心结论

  • 宏观血管侵犯、高甲胎蛋白和高中性粒细胞与淋巴细胞比值为总生存期较差的预后因素。
  • 索拉非尼获益与预后因素无关,在各亚组中均一致观察到。
  • 无肝外转移、丙型肝炎病毒感染和较低中性粒细胞与淋巴细胞比值可预测索拉非尼更大的总生存期获益。

研究设计与样本

  • 基于SHARP与亚太两项安慰剂对照III期研究的汇总探索性分析,共827例患者(索拉非尼448例,安慰剂379例)。
  • 采用Cox比例风险模型对基线变量进行单变量和多变量分析以识别总生存期的潜在预后因素。
  • 通过Cox比例风险模型评估各亚组中治疗与亚组的交互项,以确定索拉非尼获益的预测因素。

主要发现

  • 多变量分析显示,在两个治疗组中总生存期较差的强预后因素为宏观血管侵犯、高甲胎蛋白和高中性粒细胞与淋巴细胞比值(≤ vs. >中位数[3.1])。
  • 索拉非尼的总生存期获益在所有亚组中均一致观察到。
  • 与安慰剂相比,无肝外转移患者(HR 0.55 vs. 0.84)、丙型肝炎病毒感染者(HR 0.47 vs. 0.81)和低中性粒细胞与淋巴细胞比值者(HR 0.59 vs. 0.84)的索拉非尼总生存期获益显著更大。

关键数值与推荐

  • 中性粒细胞与淋巴细胞比值以中位数3.1为界(≤ vs. >中位数[3.1])。
  • 无肝外转移患者索拉非尼vs安慰剂的总生存期HR为0.55 vs. 0.84。
  • 丙型肝炎病毒感染者索拉非尼vs安慰剂的总生存期HR为0.47 vs. 0.81。
  • 低中性粒细胞与淋巴细胞比值者索拉非尼vs安慰剂的总生存期HR为0.59 vs. 0.84。

临床怎么用

  • 该探索性汇总分析结果有助于了解接受索拉非尼治疗患者的预后。
  • 该结果为设计比较新药与索拉非尼的试验提供了进一步细化信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Sorafenib, an oral multikinase inhibitor, significantly prolonged overall survival (OS) vs. placebo in patients with unresectable hepatocellular carcinoma (HCC) in two phase III studies, SHARP (Sorafenib HCC Assessment Randomized Protocol) and Asia Pacific (AP). To assess prognostic factors for HCC and predictive factors of sorafenib benefit, we conducted a pooled exploratory analysis from these placebo-controlled phase III studies. METHODS: To identify potential prognostic factors for OS, univariate and multivariate (MV) analyses were performed for baseline variables by Cox proportional hazards model. Hazard ratios (HRs) and median OS were evaluated across pooled subgroups. To assess factors predictive of sorafenib benefit, the interaction term between treatment for each subgroup was evaluated by Cox proportional hazard model. RESULTS: In 827 patients (448 sorafenib; 379 placebo) analyzed, strong prognostic factors for poorer OS identified from MV analysis in both treatment arms were presence of macroscopic vascular invasion (MVI), high alpha-fetoprotein (AFP), and high neutrophil-to-lymphocyte ratio (NLR; ⩽ vs. >median [3.1]). Sorafenib OS benefit was consistently observed across all subgroups. Significantly greater OS sorafenib benefit vs. placebo was observed in patients without extrahepatic spread (EHS; HR, 0.55 vs. 0.84), with hepatitis C virus (HCV) (HR, 0.47 vs. 0.81), and a low NLR (HR, 0.59 vs. 0.84). CONCLUSIONS: In this exploratory analysis, presence of MVI, high AFP, and high NLR were prognostic factors of poorer OS. Sorafenib benefit was consistently observed irrespective of prognostic factors. Lack of EHS, HCV, and lower NLR were predictive of a greater OS benefit with sorafenib. LAY SUMMARY: This exploratory pooled analysis showed that treatment with sorafenib provides a survival benefit in all subgroups of patients with HCC; however, the magnitude of benefit is greater in patients with disease confined to the liver (without extrahepatic spread), or in those with hepatitis C virus, or a lower neutrophil-to-lymphocyte ratio, an indicator of inflammation status. These results help inform the prognosis of patients receiving sorafenib therapy and provide further refinements for the design of trials testing new agents vs. sorafenib. Clinical Trial Numbers: NCT00105443 and NCT00492752.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017. PMID: 28687477. doi:10.1016/j.jhep.2017.06.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。